Nuzenio

Phase Iii Igan

Phase Iii Igan news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 3 latest news signals 4 publisher sources 100/100 entity strength

Latest news

Otsuka reports VOYXACT phase 3 eGFR gain in IgA nephropathy - International Business TimesInternational Business Times · Tue, 04 Aug 2026 14:43:23 GMT Otsuka Unveils Phase 3 VOYXACT Results for IgA Nephropathy Treatment - World Business OutlookWorld Business Outlook · Tue, 04 Aug 2026 05:40:13 GMT In a first, Otsuka’s Voyxact stabilizes IgAN patients’ kidney function decline to normal levels - Fierce PharmaFierce Pharma · Mon, 03 Aug 2026 21:00:00 GMT Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy - Business WireBusiness Wire · Mon, 03 Aug 2026 21:00:00 GMT

Timeline

Tue, 04 Aug 2026 14:43:23 GMTOtsuka reports VOYXACT phase 3 eGFR gain in IgA nephropathy - International Business Times

Tue, 04 Aug 2026 05:40:13 GMTOtsuka Unveils Phase 3 VOYXACT Results for IgA Nephropathy Treatment - World Business Outlook

Mon, 03 Aug 2026 21:00:00 GMTIn a first, Otsuka’s Voyxact stabilizes IgAN patients’ kidney function decline to normal levels - Fierce Pharma

Mon, 03 Aug 2026 21:00:00 GMTOtsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy - Business Wire

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

Otsuka4 live mentions International Business Times3 live mentions World Business Outlook3 live mentions VOYXACT2 live mentions IgA2 live mentions Otsuka Unveils Phase2 live mentions VOYXACT Results2 live mentions IgA Nephropathy Treatment2 live mentions Voyxact2 live mentions IgAN2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Phase Iii Igan.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

4 distinct publisher/source names are currently connected to this entity page.